Dipartimento di Chimica
e Tecnologie del Farmaco

In the quest for new targets in anti-tumor therapy the proteasome and its inhibitors have been in the focus of academic and industrial research. In this context, we recently reported on the p27 stabilization effect of argyrin A through selective inhibition of the proteasome1. The talk will cover the synthesis of novel argyrines through a route that takes advantage of modern synthetic transformations and thus allows medicinal application by avoiding pharmacologically problematic functional group manipulations such as the incorporation of selenium compounds2.